{"id":1209,"date":"2025-07-27T16:35:00","date_gmt":"2025-07-27T16:35:00","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1209"},"modified":"2025-11-14T10:33:50","modified_gmt":"2025-11-14T10:33:50","slug":"admit-therapeutics-attending-aaic-2025-in-toronto","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-attending-aaic-2025-in-toronto\/","title":{"rendered":"ADmit Therapeutics\u00a0is Attending the AAIC 2025 in Toronto"},"content":{"rendered":"\n<p>Barcelona, July 27, 2025. We are excited to announce that our company is attending the\u00a0<strong>Alzheimer\u2019s Association International Conference 2025 (AAIC25)<\/strong>\u00a0in\u00a0<strong>Toronto, Canada<\/strong>, from\u00a0<strong>July 27 to July 31, 2025<\/strong>.<\/p>\n\n\n\n<p>The&nbsp;<strong>AAIC<\/strong>&nbsp;is the world\u2019s largest and most influential meeting dedicated to advancing dementia science. Organized by the Alzheimer&#8217;s Association, this global forum brings together researchers, clinicians, and industry leaders to share the latest findings, innovations, and breakthroughs in Alzheimer\u2019s and dementia research.<\/p>\n\n\n\n<p>Our team is looking forward to connecting with fellow scientists, healthcare professionals, and partners to discuss the MAP-AD<sup>\u00ae<\/sup>&nbsp;Test and strengthen our commitment to improving the lives of those affected by Alzheimer\u2019s disease providing a prognostic tool that identifies Alzheimer\u2019s dementia progression in Mild Cognitive Impairment patients, independently of their&nbsp;b-amyloid status.<\/p>\n\n\n\n<p>If you&#8217;re attending #AAIC25, we\u2019d love to meet you! Reach out to connect with us during the conference  at booth #1614 and poster #98536.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-1024x576.jpg\" alt=\"\" class=\"wp-image-1210\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-1024x576.jpg 1024w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-300x169.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-768x432.jpg 768w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-1536x864.jpg 1536w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2025\/07\/AAIC25-Toronto-2048x1152.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Barcelona, July 27, 2025. We are excited to announce that our company is attending the\u00a0Alzheimer\u2019s Association International Conference 2025 (AAIC25)\u00a0in\u00a0Toronto, Canada, from\u00a0July 27 to July 31, 2025. The&nbsp;AAIC&nbsp;is the world\u2019s largest and most influential meeting dedicated to advancing dementia science. Organized by the Alzheimer&#8217;s Association, this global forum brings together researchers, clinicians, and industry leaders [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1209","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1209"}],"version-history":[{"count":3,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1209\/revisions"}],"predecessor-version":[{"id":1387,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1209\/revisions\/1387"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}